First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in combination with the chemotherapies Taxol (paclitaxel) and Platinol (cisplatin).
Tyvyt is intended to boost anti-cancer immune responses by targeting the PD-1 and PD-L1 proteins. When bound, these two proteins prevent the immune system from attacking cancer cells. By targeting the proteins and blocking their interactions, Tyvyt shows promise in fighting the disease.